Emerging disease-modifying therapies for sickle cell disease
نویسندگان
چکیده
منابع مشابه
Emerging oral disease-modifying therapies
Over the last two decades, patients have relied on the use of self-injectable disease modifying agents for the treatment of multiple sclerosis. The need for frequent injections has affected treatment up take and adherence. Fingolimod, the first oral disease modifying agent to be licensed in Europe and the United States, has been shown to be effective in reducing relapse rates in comparison to p...
متن کاملProponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease
Sickle cell disease (SCD) is an inherited blood disorder that primarily affects African-American and other ethnic minority populations. There are three available disease-modifying therapies for sickle cell disease: hydroxyurea (HU), bone marrow transplantation (BMT), and chronic blood transfusion (CBT). Since these treatments vary in their therapeutic intent, efficacy in preventing progression ...
متن کاملNeonatal Screening for Sickle Cell Disease in Southwest Iran
the risk of sickle cell complications that is a common hemoglobin disorder in Southwest Iran. This study aimed at determining the incidence of Sickle Cell Disease (SCD) and other Hemoglobinopathies in newborn being at risk based on ethnic origin. Materials and Methods: In this descriptive epidemiologic study, between September 2013 and September 2015, 8363 newborn blood samples were test...
متن کاملIntracardiac Thrombosis in Sickle Cell Disease
In patients with sickle cell disease, thrombotic microangiopathy is a rare complication. Also in sickle cell disease, intracardiac thrombus formation without structural heart diseases or atrial arrhythmias is a rare phenomenon. We herein describe a 22-year-old woman, who was a known case of sickle cell-βthalassemia, had a history of recent missed abortion, and was admitted with a vaso-occlusive...
متن کاملNovel therapies in sickle cell disease.
Despite an increased understanding of the pathophysiology of sickle cell disease (SCD), there remains a paucity of available agents for the prevention and treatment of specific SCD-related complications. Recently, there has been significant progress in the development of novel drugs for this disease. These agents, which increase the production of fetal hemoglobin, improve red blood cell hydrati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Haematologica
سال: 2019
ISSN: 0390-6078,1592-8721
DOI: 10.3324/haematol.2018.207357